Cargando…

Integrating in vitro metabolomics with a 96-well high-throughput screening platform

INTRODUCTION: High-throughput screening (HTS) is emerging as an approach to support decision-making in chemical safety assessments. In parallel, in vitro metabolomics is a promising approach that can help accelerate the transition from animal models to high-throughput cell-based models in toxicity t...

Descripción completa

Detalles Bibliográficos
Autores principales: Malinowska, Julia M., Palosaari, Taina, Sund, Jukka, Carpi, Donatella, Bouhifd, Mounir, Weber, Ralf J. M., Whelan, Maurice, Viant, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743266/
https://www.ncbi.nlm.nih.gov/pubmed/35000038
http://dx.doi.org/10.1007/s11306-021-01867-3
_version_ 1784629872627286016
author Malinowska, Julia M.
Palosaari, Taina
Sund, Jukka
Carpi, Donatella
Bouhifd, Mounir
Weber, Ralf J. M.
Whelan, Maurice
Viant, Mark R.
author_facet Malinowska, Julia M.
Palosaari, Taina
Sund, Jukka
Carpi, Donatella
Bouhifd, Mounir
Weber, Ralf J. M.
Whelan, Maurice
Viant, Mark R.
author_sort Malinowska, Julia M.
collection PubMed
description INTRODUCTION: High-throughput screening (HTS) is emerging as an approach to support decision-making in chemical safety assessments. In parallel, in vitro metabolomics is a promising approach that can help accelerate the transition from animal models to high-throughput cell-based models in toxicity testing. OBJECTIVE: In this study we establish and evaluate a high-throughput metabolomics workflow that is compatible with a 96-well HTS platform employing 50,000 hepatocytes of HepaRG per well. METHODS: Low biomass cell samples were extracted for metabolomics analyses using a newly established semi-automated protocol, and the intracellular metabolites were analysed using a high-resolution spectral-stitching nanoelectrospray direct infusion mass spectrometry (nESI-DIMS) method that was modified for low sample biomass. RESULTS: The method was assessed with respect to sensitivity and repeatability of the entire workflow from cell culturing and sampling to measurement of the metabolic phenotype, demonstrating sufficient sensitivity (> 3000 features in hepatocyte extracts) and intra- and inter-plate repeatability for polar nESI-DIMS assays (median relative standard deviation < 30%). The assays were employed for a proof-of-principle toxicological study with a model toxicant, cadmium chloride, revealing changes in the metabolome across five sampling times in the 48-h exposure period. To allow the option for lipidomics analyses, the solvent system was extended by establishing separate extraction methods for polar metabolites and lipids. CONCLUSIONS: Experimental, analytical and informatics workflows reported here met pre-defined criteria in terms of sensitivity, repeatability and ability to detect metabolome changes induced by a toxicant and are ready for application in metabolomics-driven toxicity testing to complement HTS assays. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11306-021-01867-3.
format Online
Article
Text
id pubmed-8743266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-87432662022-01-20 Integrating in vitro metabolomics with a 96-well high-throughput screening platform Malinowska, Julia M. Palosaari, Taina Sund, Jukka Carpi, Donatella Bouhifd, Mounir Weber, Ralf J. M. Whelan, Maurice Viant, Mark R. Metabolomics Original Article INTRODUCTION: High-throughput screening (HTS) is emerging as an approach to support decision-making in chemical safety assessments. In parallel, in vitro metabolomics is a promising approach that can help accelerate the transition from animal models to high-throughput cell-based models in toxicity testing. OBJECTIVE: In this study we establish and evaluate a high-throughput metabolomics workflow that is compatible with a 96-well HTS platform employing 50,000 hepatocytes of HepaRG per well. METHODS: Low biomass cell samples were extracted for metabolomics analyses using a newly established semi-automated protocol, and the intracellular metabolites were analysed using a high-resolution spectral-stitching nanoelectrospray direct infusion mass spectrometry (nESI-DIMS) method that was modified for low sample biomass. RESULTS: The method was assessed with respect to sensitivity and repeatability of the entire workflow from cell culturing and sampling to measurement of the metabolic phenotype, demonstrating sufficient sensitivity (> 3000 features in hepatocyte extracts) and intra- and inter-plate repeatability for polar nESI-DIMS assays (median relative standard deviation < 30%). The assays were employed for a proof-of-principle toxicological study with a model toxicant, cadmium chloride, revealing changes in the metabolome across five sampling times in the 48-h exposure period. To allow the option for lipidomics analyses, the solvent system was extended by establishing separate extraction methods for polar metabolites and lipids. CONCLUSIONS: Experimental, analytical and informatics workflows reported here met pre-defined criteria in terms of sensitivity, repeatability and ability to detect metabolome changes induced by a toxicant and are ready for application in metabolomics-driven toxicity testing to complement HTS assays. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11306-021-01867-3. Springer US 2022-01-09 2022 /pmc/articles/PMC8743266/ /pubmed/35000038 http://dx.doi.org/10.1007/s11306-021-01867-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Malinowska, Julia M.
Palosaari, Taina
Sund, Jukka
Carpi, Donatella
Bouhifd, Mounir
Weber, Ralf J. M.
Whelan, Maurice
Viant, Mark R.
Integrating in vitro metabolomics with a 96-well high-throughput screening platform
title Integrating in vitro metabolomics with a 96-well high-throughput screening platform
title_full Integrating in vitro metabolomics with a 96-well high-throughput screening platform
title_fullStr Integrating in vitro metabolomics with a 96-well high-throughput screening platform
title_full_unstemmed Integrating in vitro metabolomics with a 96-well high-throughput screening platform
title_short Integrating in vitro metabolomics with a 96-well high-throughput screening platform
title_sort integrating in vitro metabolomics with a 96-well high-throughput screening platform
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743266/
https://www.ncbi.nlm.nih.gov/pubmed/35000038
http://dx.doi.org/10.1007/s11306-021-01867-3
work_keys_str_mv AT malinowskajuliam integratinginvitrometabolomicswitha96wellhighthroughputscreeningplatform
AT palosaaritaina integratinginvitrometabolomicswitha96wellhighthroughputscreeningplatform
AT sundjukka integratinginvitrometabolomicswitha96wellhighthroughputscreeningplatform
AT carpidonatella integratinginvitrometabolomicswitha96wellhighthroughputscreeningplatform
AT bouhifdmounir integratinginvitrometabolomicswitha96wellhighthroughputscreeningplatform
AT weberralfjm integratinginvitrometabolomicswitha96wellhighthroughputscreeningplatform
AT whelanmaurice integratinginvitrometabolomicswitha96wellhighthroughputscreeningplatform
AT viantmarkr integratinginvitrometabolomicswitha96wellhighthroughputscreeningplatform